Halozyme (HALO) director receives RSU grant and 6,040-share option

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Henderson Jeffrey William reported acquisition or exercise transactions in this Form 4 filing.

HALOZYME THERAPEUTICS director Jeffrey William Henderson received equity compensation in the form of stock and options. He was granted 3,796 restricted stock units, each representing one share of common stock, and an option to purchase 6,040 shares at $65.87 per share.

The RSU and stock option grants are part of the company’s director compensation program. Both awards vest in full on the earlier of May 5, 2027 or the date of the company’s next annual meeting of stockholders. Following the grants, he directly holds 36,572 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Henderson Jeffrey William

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	6,040	$0.00	--
Grant/Award	Common Stock	3,796	$0.00	--

Holdings After Transaction: Option to Purchase Common Stock — 6,040 shares (Direct, null); Common Stock — 36,572 shares (Direct, null)

Footnotes (1)

Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Key Figures

RSU grant size: 3,796 units Option grant size: 6,040 shares Option exercise price: $65.87 per share +3 more

6 metrics

RSU grant size 3,796 units Annual restricted stock unit grant to director on May 5, 2026

Option grant size 6,040 shares Stock option to purchase common stock granted May 5, 2026

Option exercise price $65.87 per share Exercise price for 6,040-share stock option grant

Post-grant holdings 36,572 shares Common stock directly held after RSU grant

Option expiration May 5, 2036 Expiration date of stock option grant

Vesting date trigger May 5, 2027 Latest vesting date for RSUs and options, or earlier annual meeting

Key Terms

restricted stock unit ("RSU"), director compensation program, stock option grant, annual meeting of stockholders

4 terms

restricted stock unit ("RSU") financial

"Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program."

director compensation program financial

"Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program."

stock option grant financial

"Represents annual stock option grant under the Issuer's director compensation program."

annual meeting of stockholders financial

"will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders."

Form 4 Insider Transactions: What Each Field Means →

05/07/2026 - 07:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Henderson Jeffrey William

(Last)

(First)

(Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/05/2026		A		3,796⁽¹⁾	A	$0	36,572	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option to Purchase Common Stock	$65.87	05/05/2026		A		6,040		⁽²⁾	05/05/2036	Common Stock	6,040	$0	6,040	D

Explanation of Responses:

1. Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

2. Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did HALO (Halozyme Therapeutics) director Jeffrey Henderson receive?

Director Jeffrey Henderson received 3,796 restricted stock units and a stock option for 6,040 shares at $65.87. These awards are part of Halozyme’s director compensation program and provide additional equity-based incentives tied to the company’s common stock performance.

Are Jeffrey Henderson’s new HALO awards open-market purchases or compensation grants?

The awards are compensation grants, not open-market purchases. Henderson received 3,796 restricted stock units and an option for 6,040 shares at $65.87 as part of Halozyme’s director compensation program, with no cash paid per share at grant.

When do Jeffrey Henderson’s new Halozyme RSU and option grants vest?

Both the 3,796 restricted stock units and the 6,040-share stock option vest in full on the earlier of May 5, 2027 or the date of Halozyme’s next annual meeting of stockholders, aligning director incentives with shareholder-focused milestones.

What is Jeffrey Henderson’s Halozyme shareholding after these Form 4 transactions?

After the grants, Jeffrey Henderson directly holds 36,572 shares of Halozyme common stock. He also holds an option to purchase 6,040 additional shares at $65.87, which, if exercised in the future, would increase his direct equity exposure to the company.

What is the exercise price and expiration date of Jeffrey Henderson’s new HALO stock option?

The newly granted stock option allows purchase of 6,040 Halozyme common shares at $65.87 per share. According to the disclosure, the option expires on May 5, 2036, giving a long-term window for potential exercise after vesting completes.